Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.

Revenue projections:

Revenue projections for JUBLINGREA
Revenue projections for JUBLINGREA

Investors are expected to be cautious with JUBLINGREA, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.323000
forwardPE 26.802282
debtToEquity 26.094000
earningsGrowth 1.508000
revenueGrowth -0.022000
grossMargins 0.384620
operatingMargins 0.102070
trailingEps 15.870000
forwardEps 0.000000

Jubilant Ingrevia Limited's current ratio, being 1.323, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, Jubilant Ingrevia Limited is well-equipped to meet its immediate financial obligations without any difficulties.
JUBLINGREA's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
JUBLINGREA's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.

Price projections:

Price projections for JUBLINGREA
Price projections for JUBLINGREA

Over time, price projections for Jubilant Ingrevia Limited have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for Jubilant Ingrevia Limited's continued growth.

Recommendation changes over time:

Recommendations trend for JUBLINGREA
Recommendations trend for JUBLINGREA


A recent buy bias from analysts toward JUBLINGREA indicates strong confidence in the stock's future performance. This could encourage investors to park their money in JUBLINGREA, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.